TargetGag-Pol polyprotein [588-1147,K652R,M771V](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: 1.04E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [588-1147,M628L,D654N,M771V,L797W,T802Y](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: 5.39E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [588-1147,M628L,T656S,M771V,L797W,T802Y](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: >6.47E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [588-1147,V662I,F664L,F703Y,Q738M,M771V](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: >6.49E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [588-1147,M628L,N654N,K657R,T802F,K807E](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: 6.52E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein [588-1147,M628L,D654N,M771V,L797W,T802Y](Human immunodeficiency virus type 1 group M subtyp...)
Chimerix
US Patent
Chimerix
US Patent
Affinity DataIC50: >8.51E+3nMAssay Description:The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), nonnucle...More data for this Ligand-Target Pair
Affinity DataIC50: >1.33E+5nMAssay Description:Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to ...More data for this Ligand-Target Pair
Affinity DataIC50: >1.33E+5nMAssay Description:Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ...More data for this Ligand-Target Pair
Affinity DataIC50: >1.33E+5nMAssay Description:Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and...More data for this Ligand-Target Pair
Affinity DataIC50: >1.33E+5nMAssay Description:Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and...More data for this Ligand-Target Pair